Stock FRE FIREBRICK PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Firebrick Pharma Limited

Equities

FRE

AU0000197352

Market Closed - Australian S.E.
Other stock markets
 11:40:57 27/06/2024 am IST 		5-day change 1st Jan Change
0.056 AUD +7.69% Intraday chart for Firebrick Pharma Limited -1.75% +12.00%
13/06 Firebrick Pharma Launches Nasodine Nasal Spray in Singapore MT
23/05 Firebrick Pharma Obtains Nasodine Composition Patent in South Africa MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Firebrick Pharma Launches Nasodine Nasal Spray in Singapore
MT
Firebrick Pharma Obtains Nasodine Composition Patent in South Africa
MT
Firebrick Pharma Raises AU$800,000 via Placement
MT
Firebrick Pharma's Nasodine Nasal Spray Enters US Market
MT
Firebrick Pharma Phase 2 Covid-19 Trial Published in Laryngoscope Journal
MT
Firebrick Pharma Gets Coverage Extension of COVID-19 Patent in US
MT
Firebrick Pharma Limited Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Firebrick Pharma Withdraws Appeal Against Regulator's Decision Over Nasodine Nasal Spray
MT
Firebrick Pharma's Nasodine Nasal Spray COVID-19 Patent Granted in South Africa
MT
Firebrick Pharma Receives AU$1.8 Million R&D Tax Rebate
MT
Firebrick Pharma Limited Announces That Trial Statisticians Have Completed Their Efficacy Analysis of the Headline Results in the Phase 3 Trial of Nasodine® Nasal Spray as A Treatment for the Common Cold
CI
Firebrick Pharma Limited Reports Earnings Results for the Full Year Ended June 30, 2023
CI
Firebrick Pharma's Nasal Spray Patent Allowed in Canada
MT
Firebrick Pharma Limited Announces Resume of Phase 3 Clinical Trial of Nasodine Nasal Spray
CI
Firebrick Pharma Files Pediatric Investigation Plan in Europe for Common Cold Treatment
MT
Firebrick Pharma Limited Reports Earnings Results for the Half Year Ended December 31, 2022
CI
Firebrick Pharma Limited Reports Earnings Results for the Half Year Ended December 31, 2022
CI
Firebrick Pharma Identifies New Indication for Nasal Spray Product
MT
Firebrick Pharma Rises 11% After Getting Australian Patent for Nasodine Nasal Spray
MT
Firebrick Pharma Receives $700,000 R&D Tax Rebate
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FRE Stock
  4. News Firebrick Pharma Limited
  5. Highlights